SERT, IL-IR, and p38 MAPK-dependent behavioral effects of LPS. (a) C57BL/6 mice were injected with saline (n=8) or LPS (0.2, 1.0, and 5.0 mg/kg i.p., n=6 for each dose). Total activity was monitored during the indicated time. Total activity of mice tested 20 min before treatment served as the control condition. Total activity at 24, 48, and 72 h time points was measured for 20 min. *p<0.05; **p<0.01 vs saline control. (b) Time-response of LPS in TST. Saline or LPS (0.2 mg/kg i.p.) was injected to C57BL/6 mice and the TST was conducted at the indicated time points (n=6 for each condition). (c) C57BL/6 mice were injected with saline, LPS (0.2 mg/kg), SB203580 (50 μg/kg), or SB203580 (50 μg/kg) 10 min before LPS (0.2 mg/kg). TST was conducted 60 min after the last injection (n=6–10). (d) C57BL/6 wild-type or IL-1R intact or IL-1R knockout mice (all with C57BL/6 background) were administered saline or LPS (0.2 mg/kg i.p.). TST was conducted 60 min after the last injection (n=6 for each condition). (e) C57BL/6 wild-type or SERT knockout (KO) mice were administered saline or LPS (0.2 mg/kg i.p). TST was conducted 60 min after the last injection (n=6 for each condition). (f) C57BL/6 mice were injected with saline, LPS (0.2 mg/kg), SB203580 (50 μg/kg), or SB203580 (50 μg/kg) 10 min before LPS (0.2 mg/kg). FST was conducted 60 min after the last injection (n=6 for each condition).